LDLR and familial hyperaldosteronism: Thus, the presence of the LDLR-c.313+1G>A mutation fully accounts for the clinical FH phenotype (Table 2), whereas the first test result of the reference laboratory, that is, absence of the initial FH mutation LDLR-c.1359−1, would have left the phenotype with hypercholesterolemia unexplained.